OSE Immunotherapeutics Announces Strategic Plan for 2026–2028

OSE Immunotherapeutics has unveiled a strategic plan for 2026–2028, focusing on value creation through four key initiatives. Central to the plan is the completion of the Tedopi Phase 3 trial for Non-Small Cell Lung Cancer, with results expected by early 2028. This trial is proceeding at a low additional cost. Another priority is the development of Lusvertikimab for rare diseases, promising modest investment and potentially quicker market access.

Lusvertikimab is also being explored in a subcutaneous form for Ulcerative Colitis, aimed at partnering once bioequivalence data is affirmed. There is a focus on sustaining scientific leadership, maximizing intellectual property value, and fostering innovation.

Financially, OSE Immunotherapeutics seeks to minimize shareholder dilution and secure resources through diverse financing and strategic partnerships. They aim to balance risk and return, prioritizing late-stage assets for maximum impact.